(Q35917319)

11 August 2017

1 reference

title

Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts (English)

1 reference

11 August 2017

1 reference

Raymund R Razonable

1

1 reference

11 August 2017

Carlos V Paya

series ordinal

2

1 reference

11 August 2017

publication date

1 February 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

27-41

1 reference

Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Pharmacokinetics of valganciclovir and ganciclovir in renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Ganciclovir induces reproductive hazards in male rats after short-term exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.27

21 January 2018

Identifiers

DOI

10.1586/14787210.2.1.27

1 reference

11 August 2017

1 reference